Hypothesis

Aging‑associated shrinkage of the lymphoid‑supportive bone marrow niche drives oligoclonal B cell expansion, which in turn fuels CD4 T cell immunosenescence via aberrant MHCII presentation. Restoring a youthful niche will renew polyclonal B cell output, lower pathogenic MHCII‑dependent T cell help, reduce inflammaging, and extend healthspan.

Mechanistic Rationale

Clonal B cells accumulate with age and present self‑antigens derived from senescent cells through MHCII, providing help to CD4 T cells that adopt a Tfh‑like, inflammatory phenotype [1]. This loop amplifies SASP production and tissue damage. The root cause is a myeloid‑skewed hematopoietic stem cell (HSC) bias and diminished CXCL12‑abundant stromal cells that limit pro‑B maturation [2,3]. If the niche is re‑programmed to increase lymphoid‑friendly signals, precursor B cell flux should rise, diversifying the repertoire and diluting clonal expansions. Fewer clonally expanded B cells mean less MHCII‑loaded self‑peptide availability, weakening the pathogenic CD4 T cell help that sustains inflammaging.

Experimental Design

1. Niche rejuvenation – Treat 20‑month‑old C57BL/6 mice with either (a) intravenous infusion of young mesenchymal stromal cells (MSCs) enriched for CXCL12 high expression, or (b) sustained release of a CXCL12 agonist hydrogel implanted in the femur marrow cavity.
2. Controls – Age‑matched mice receiving vehicle or old MSCs.
3. Readouts (4‑week intervals) –
   • Flow cytometry of bone marrow: pro‑B (B220+CD43+IgM−) frequency, HSC lymphoid‑myeloid bias (LSK CD150+CD48−).
   • Peripheral B cell repertoire sequencing: Shannon entropy, clonal expansion size.
   • MHCII surface density on B cells (flow).
   • CD4 T cell phenotype: naïve (CD62LhiCD44lo), Tfh‑like (CXCR5+PD-1+), senescence markers (KLRG1+CD57+).
   • Serum inflammaging cytokines (IL‑6, TNF‑α, CCL2) via Luminex.
   • Frailty index and grip strength.
   • Lifespan monitoring (n=30 per group).

Predicted Outcomes

• Niche‑treated mice will show a 2‑fold increase in bone marrow pro‑B cells and a shift toward lymphoid HSC output.
• Peripheral B cell repertoires will exhibit higher diversity (entropy ↑30%) and reduced size of the top 5 clones.
• MHCII MFI on B cells will drop by ~25%, correlating with decreased CD4 Tfh‑like expansion.
• Serum IL‑6 and TNF‑α will decline to levels comparable to 6‑month‑old mice.
• Frailty scores will improve by 20% and median lifespan will extend by ~15% relative to vehicle controls.

Potential Pitfalls and Alternatives

If niche intervention fails to alter B cell clonality, the hypothesis would be falsified, suggesting that B cell‑driven inflammaging is independent of marrow output or that other APCs (e.g., macrophages) dominate the MHCII‑dependent CD4 T cell help. In that case, targeting B cell MHCII directly (using conditional CD19‑Cre MHCII knockout in aged mice) would be the next test.

This framework transforms the observation that "the immune system doesn’t protect you from aging — it is aging" into a precise, actionable lever: restoring the bone marrow niche to reset lymphocyte production and break the B‑cell‑centric inflammaging circuit.